Evidence map›Paper›PMID 40710702›Full record

ArticleGels (Basel, Switzerland)2025

Succinimidyl Alginate-Modified Fibrin Hydrogels from Human Plasma for Skin Tissue Engineering.

Ana Matesanz, Raúl Sanz-Horta, Alberto Gallardo, Cristina Quílez, Helmut Reinecke, Pablo Acedo, Diego Velasco, Enrique Martínez-Campos, José Luis Jorcano, Carlos Elvira

Abstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ana MatesanzDepartment of Bioengineering, Universidad Carlos III de Madrid (UC3M), 28911 Madrid, Spain.ORCID 0000-0001-7135-9422
Raúl Sanz-HortaDepartment of Applied Macromolecular Chemistry, Institute of Polymer Science and Technology, Spanish National Research Council (ICTP-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.ORCID 0000-0002-1375-8473
Alberto GallardoDepartment of Applied Macromolecular Chemistry, Institute of Polymer Science and Technology, Spanish National Research Council (ICTP-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.
Cristina QuílezDepartment of Bioengineering, Universidad Carlos III de Madrid (UC3M), 28911 Madrid, Spain.
Helmut ReineckeDepartment of Applied Macromolecular Chemistry, Institute of Polymer Science and Technology, Spanish National Research Council (ICTP-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.
Pablo AcedoDepartment of Electronic Technology, Universidad Carlos III de Madrid (UC3M), 28911 Madrid, Spain.ORCID 0000-0002-8053-7363
Diego VelascoDepartment of Bioengineering, Universidad Carlos III de Madrid (UC3M), 28911 Madrid, Spain.ORCID 0000-0002-1531-1595
Enrique Martínez-CamposDepartment of Applied Macromolecular Chemistry, Institute of Polymer Science and Technology, Spanish National Research Council (ICTP-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.
José Luis JorcanoDepartment of Bioengineering, Universidad Carlos III de Madrid (UC3M), 28911 Madrid, Spain.
Carlos ElviraDepartment of Applied Macromolecular Chemistry, Institute of Polymer Science and Technology, Spanish National Research Council (ICTP-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.ORCID 0000-0001-6007-5774

Funding

Comunidad de Madrid S2018/BAA-4480Fundación Ramón Areces CátedraMinisterio de Ciencia, Innovación y Universidades RTI2018-101627-B-I00
6 · The paper itself

Abstract

Plasma-derived fibrin hydrogels are widely used in tissue engineering because of their excellent biological properties. Specifically, human plasma-derived fibrin hydrogels serve as 3D matrices for autologous skin graft production, skeletal muscle repair, and bone regeneration. Nevertheless, for advanced applications such as in vitro skin equivalents and engineered grafts, the intrinsic limitations of native fibrin hydrogels in terms of long-term mechanical stability and resistance to degradation need to be addressed to enhance the usefulness and application of these hydrogels in tissue engineering. In this study, we chemically modified plasma-derived fibrin by incorporating succinimidyl alginate (SA), a version of alginate chemically modified to introduce reactive succinimidyl groups. These NHS ester groups (N-hydroxysuccinimide esters), attached to the alginate backbone, are highly reactive toward the primary amine groups present in plasma proteins such as fibrinogen. When mixed with plasma, the NHS groups covalently bond to the amine groups in fibrin, forming stable amide linkages that reinforce the fibrin network during hydrogel formation. This chemical modification improved mechanical properties, reduces contraction, and enhanced the stability of the resulting hydrogels. Hydrogels were prepared with a final fibrinogen concentration of 1.2 mg/mL and SA concentrations of 0.5, 1, 2, and 3 mg/mL. The objective was to evaluate whether this modification could create a more stable matrix suitable for supporting skin tissue development. The mechanical and microstructure properties of these new hydrogels were evaluated, as were their biocompatibility and potential to create 3D skin models in vitro. Dermo-epidermal skin cultures with primary human fibroblast and keratinocyte cells on these matrices showed improved dermal stability and better tissue structure, particularly SA concentrations of 0.5 and 1 mg/mL, as confirmed by H&E (Hematoxylin and Eosin) staining and immunostaining assays. Overall, these results suggest that SA-functionalized fibrin hydrogels are promising candidates for creating more stable in vitro skin models and engineered skin grafts, as well as for other types of engineered tissues, potentially.

Indexed as

dermo-epidermal equivalentsfibrin hydrogelsin vitro human skin tissue engineeringplasma-derived fibrin hydrogelsuccinimidyl alginatetissue engineering

Identifiers

PMID40710702
PMCPMC12294349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.